我们的网站为什么显示成这样?

可能因为您的浏览器不支持样式,您可以更新您的浏览器到最新版本,以获取对此功能的支持,访问下面的网站,获取关于浏览器的信息:

|本期目录/Table of Contents|

真武通脉汤治疗脾肾阳虚型糖尿病肾病临床观察(PDF)

《云南中医学院学报》[ISSN:1000-2723/CN:53-1048/R]

期数:
2015年05期
页码:
65-69
栏目:
临床研究
出版日期:
2015-09-25

文章信息/Info

Title:
Clinical Observation on Zhenwu Tongmai Decoction on Spleen-kidney Yang Deficiencyof Type 2 Diabetic Nephropathy
作者:
蓝元隆苏小惠洪杨华刘雪娜方镇福黄连河施兆明戴秀娟罗金国刘垠浩陈丽贞戴舜珍
福建省漳州市中医院,福建 漳州 363000
Author(s):
LAN Yuanlong SU Xiaohui HONG Yanghua LIU Xuena FANG ZhenfuHUANG Lianhe SHI Zhaoming DAI Xiujuan LUO Jinguo LIU YinhaoCHEN Lizhen DAI Shunzhen
Zhangzhou Hospital of Traditional Chinese Medicine, Zhangzhou 363000, China
关键词:
真武通脉汤 2型糖尿病 糖尿病肾病 脾肾阳虚
Keywords:
Zhenwu Tongmai decoction type 2 diabetes mellitus diabetic nephropathy Spleen-kidney Yang deficiency
分类号:
R255.4
DOI:
-
文献标识码:
A
摘要:
目的观察真武通脉汤治疗脾肾阳虚型糖尿病肾病(Ⅳ期)患者的临床疗效。方法将脾肾阳虚型糖尿病肾病(Ⅳ期)患者65例随机分为对照组(34例)和治疗组(31例),治疗组在对照组常规治疗的基础上加用真武通脉汤,观察治疗前后血压、血糖、血脂、血电解质、血肌酐、晨尿微量白蛋白等。结果治疗后治疗组中舒张压、空腹血糖、胆固醇、甘油三酯、晨尿微量白蛋白明显低于对照组(P<0.05);与治疗前比较,治疗组高密度脂蛋白明显升高(P<0.05),对血肌酐的影响略逊于对照组;治疗组的症状积分改善程度和临床总有效率优于对照组(P<0.05)。结论真武通脉汤改善脾肾阳虚型糖尿病肾病(Ⅳ期)患者危险因素,改善临床症状,提高临床疗效。
Abstract:
Objective To investigate the influence of spleen-kidney yang deficiency in type 2 diabetic nephropathy patients by Zhenwu Tongmai decoction. Methods 65 Spleen-kidney yang deficiency of type 2 diabetic nephropathy(4 stage) patients were randomly assigned to two groups. Patients in the control group(n=34) were given conventional antidiabetic treatment, patients in the treatment group(n=34) plus Zhenwu Tongmai decoction. 8 weeks after treatment, the changes of blood pressure, blood glucose, blood lipids, blood electrolytes, Serum creatinine(Scr), morning micro urinary albumin(UMA), TCM syndrome, and symptom scores and clinical efficacy were observed. Results After intervention, in treated groups, diastolic pressure(DBP), fasting plasma glucose(FBG), cholesterol(TC), triglyceride(TG), UMA were significantly decreased compared with the control group(P<0.05), compared with before treatment, high density lipoprotein cholesterol(HDL) were significantly increase in treated group(P<0.05). Serum creatinine was less significantly decreased compared with the control group. After treatment, symptom scores decreased in both two groups compared with before treatment(P<0.01), and both of them in treated group were better than in control group(P<0.05). Conclusion Zhenwu Tongmai decoction had better effect on improving risk factors in spleen-kidney yang deficiency of type 2 diabetic nephropathy patients. and improved the clinical symptoms and overall efficiency of clinical treatment.

参考文献/References

[1] Lu B,Gong W,Yang Z,et a1. An evaluation of the diabetic kidney disease definition in chinese patients diagnosed with type 2 diabetes mellitus[J]. J Int Med Res,2009,37(5):1493-1500.
[2] 汪珊珊,陈冬,陈明卫,等. 代谢综合征对2型糖尿病患者糖尿病肾病的影响分析[J]. 中国慢性病预防与控制,2011,19(5):509-511.
[3] 许荣,钟一红,陈波,等. 上海市郊区2型糖尿病患者肾脏疾病及其危险因素研究[J]. 中华内科杂志,2012,51(1):18-23.
[4] 中华中医药学会. 糖尿病肾病中医防治指南[J]. 中国中医药现代远程教育,2011,9(4),151-153.
[5] 林兰. 中西医结合糖尿病诊疗标准(草案)[J]. 中国中西医结合杂志,2005,25(1):94-95.
[6] Cohen KL,Harris S. Efficacy and safety of nonsteroidal anti-inflammatory drugs in the therapy of diabetic neuropathy[J]. Arch Intern Med,1987,147(8):1442-1444.
[7] 郑筱萸. 中药新药临床研究指导原则[M]. 北京:中国医药科技出版社,2002:296-298.
[8] Keane WF,Zhang Z,Lyle PA,et al. Risk scores for predicting outcomes in patients with type 2 diabetes and nephropathy:the RENAAL study[J]. Clin J Am Soc Nephrol,2006,1(4):761-767.
[9] Gowdak LH,Arantes RL,Paula FJ,et al. Underuse of American College of Cardiology/ American Heart Association Guidelines in hemodialysis patients[J]. Ren Fail,2007,29(5):559-565.
[10] Stenvinkel P. Chronic kidney disease:a public health priority and harbinger of premature cardiovascular disease[J]. J Intern Med,2010,268(5):456-467.
[11] Keane WF,Brenner BM,de Zeeuw D,et a1. The risk of developing end-stage renal disease in patients with type 2 diabetes and nephropathy:the RENAAL study[J]. Kidney Int,2003,63(4):1499-1507.
[12] Jefferson JA,Shankland SJ,Pichler RH. Proteinuria in diabetic kidney disease:a mechanistic viewpoint[J]. Kidney Int,2008,74(1):22-36.
[13] 余敏. 糖尿病肾病相关基因研究进展[J]. 中国药理学通报,2008,24(11):19-22.
[14] 舒毅,钟历勇. 氧化应激与糖尿病[J]. 东南大学学报,2005,24(1):64-67.
[15] 蒋伟,刘丽秋. 糖尿病肾病发病机制研究进展[J]. 山东医药,2008,48(10):107-108.
[16] Okada S,Shikada K,Matsuda M,et al. Intercellular adhesion molecule-1-deficient mice are resistant against renal injury after induction of diabebtes[J]. Diabetes,2003,52(10):2586-2593.
[17] 周秀艳,侯振江,邢桂芝. 血清C反应蛋白与2型糖尿病肾病的关系[J]. 中国老年学杂志,2007,27(8):792-793.
[18] Navarro-Gonzalez JF,Mora-Fernandez C. The role of inflammatory eytokines in diabetic nephropathy[J]. J Am Soc Nephrol,2008,19(3):433-442.
[19] 纪志尚,刘秀英. 糖尿病肾病患者血清TNF-α水平与糖尿病肾病的关系[J]. 实用诊断与治疗杂志,2007,21(3):181-184.

备注/Memo

备注/Memo:
基金项目: 福建中医药大学校管课题项目(XB2012047);国家中医药管理局2011年全国名老中医传承工作室建设项目 (国中医药人教发[2011]4);福建中医药大学校管课题项目(XB2012044) 收稿日期: 2015 - 07 - 22 作者简介: 蓝元隆(1978-),男,福建漳州人,主治医师,医学博士,研究方向:中西医结合内分泌代谢。E-mail:meilan0460@sina.com。
更新日期/Last Update: 2015-09-20